Sofinicline: a novel nicotinic acetylcholine receptor agonist in the treatment of attention-deficit/hyperactivity disorder.

about

Neuronal effects of nicotine during auditory selective attention The Obesity-Impulsivity Axis: Potential Metabolic Interventions in Chronic Psychiatric Patients.Discontinued neuropathic pain therapy between 2009-2015.A Simple Representation of Three-Dimensional Molecular Structure.

P2860

Q35589463-8D7117DE-49FD-4D7D-8E58-E5E4CFF4805E Q37637480-E35FFB5C-90AF-49A1-A17E-6CE56B06AC9F Q38608606-6190E00F-8CC7-474D-8DBF-C52454966D03 Q45946583-3966A262-5D87-4961-AAF2-27AC1A7414FC

P2860

Sofinicline: a novel nicotinic acetylcholine receptor agonist in the treatment of attention-deficit/hyperactivity disorder.

Item

http://www.wikidata.org/entity/Q38223307

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Sofinicline: a novel nicotinic ...... eficit/hyperactivity disorder.

@en

type

Item

label

Sofinicline: a novel nicotinic ...... eficit/hyperactivity disorder.

@en

prefLabel

Sofinicline: a novel nicotinic ...... eficit/hyperactivity disorder.

@en

P1476

Sofinicline: a novel nicotinic ...... eficit/hyperactivity disorder.

@en

P2093

Carl Fleisher

http://www.w3.org/2001/XMLSchema#string

James McGough

http://www.w3.org/2001/XMLSchema#string

P2860

A qualitative review of issues arising in the use of psychostimulant medications in patients with ADHD and co‑morbid substance use disorders

The MTA at 8 Years: Prospective Follow-up of Children Treated for Combined-Type ADHD in a Multisite Study

Practice Parameter for the Assessment and Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder

Gene-environment interactions in the development of combined type ADHD: evidence for a synapse-based model

Neuronal nicotinic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: focus on cognition

The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication

A randomized, double-blind, placebo-controlled phase 2 study of α4β2 agonist ABT-894 in adults with ADHD

Efficacy and safety of the novel α₄β₂ neuronal nicotinic receptor partial agonist ABT-089 in adults with attention-deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled crossover study

An 8-week, randomized controlled trial of atomoxetine, atomoxetine plus buspirone, or placebo in adults with ADHD

ABT-089: pharmacological properties of a neuronal nicotinic acetylcholine receptor agonist for the potential treatment of cognitive disorders

P304

1157-1163

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/13543784.2014.934806

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-06-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24965900

http://www.w3.org/2001/XMLSchema#string

P921

attention

Sofinicline: a novel nicotinic acetylcholine receptor agonist in the treatment of attention-deficit/hyperactivity disorder.

about

P2860

P2860

Sofinicline: a novel nicotinic acetylcholine receptor agonist in the treatment of attention-deficit/hyperactivity disorder.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921